^
Association details:
| Biomarker: | HER-2 mutation |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + Perjeta (pertuzumab) (HER2 dimerization inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Her2-positive Lung Cancer Treated With Dedicated Drug
Excerpt:
...HER2 exon 20 mutation or insertion among which: in-frame insertions in exon 20 between codons 775 and 881 including the 12bp insertion with a duplication / insertion of 4 amino acids (YVMA) at codon 775, the 3bp insertion with a complex insertion-substitution G776>VC and point mutations L755S and G776C....
Trial ID:
Source:
Title:
Study of trastuzumab in combination with pertuzumab in patients already treated with a lung cancer harboring a Her2 mutation and receiving docetaxel
Excerpt:
...HER2 exon 20 mutation or insertion among which: in-frame insertions in exon 20 between codons 775 and 881 including the 12bp insertion with a duplication / insertion of 4 amino acids (YVMA) at codon 775, the 3bp insertion with a complex insertion-substitution G776>VC and point mutations L755S and G776C. ...
Trial ID:
Less C2 evidence
Source:
Title:
978P - Pertuzumab plus trastuzumab (P+T) in patients (pts) with lung cancer (LC) with ERBB2 mutation (mut) or amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study
Published date:
09/05/2022
Excerpt:
Combination P+T showed evidence of anti-tumor activity in heavily pre-treated pts with LC and ERBB2 mut or amp.
Trial ID:
